Although studies have shown that molecular targeting of vascular endothelial growth factor, platelet-derived growth factor, and inhibitor (PD1-PD-L1/CTLA4) to inhibit immune checkpoints can improve prognosis to a certain extent, tumor cells may grow immune to the new anti-tumor drugs. Here, VEGFA is linked to neoplasm.